ruplizumab

Ruplizumab is a humanized monoclonal IgG1κ anti-CD154 (CD40 ligand) antibody developed as an immunosuppressive agent for the treatment of autoimmune diseases such as systemic lupus erythematosus and lupus nephritis. By binding to CD154 on activated T cells and other immune cells—thereby blocking its interaction with CD40—ruplizumab inhibits T-cell-dependent B-cell activation and subsequent immune responses. The drug was developed by Biogen but has been discontinued in clinical development due to safety concerns including life-threatening thromboembolic events[1][2][3][4][7].

Brand names

Antova

Other names

Anti-CD154 monoclonal antibodyAnti-CD-154 monoclonal antibodyAnti-CD 154 monoclonal antibodyAnti-CD40 ligand antibodyAnti-CD-40 ligand antibodyAnti-CD 40 ligand antibodyAnti-CD40 ligand monoclonal antibody 5c8Anti-CD-40 ligand monoclonal antibody 5c8Anti-CD 40 ligand monoclonal antibody 5c8Anti-gp39 monoclonal antibody - BiogenAnti-gp-39 monoclonal antibody - BiogenAnti-gp 39 monoclonal antibody - BiogenCD40 ligand monoclonal antibody - BiogenCD-40 ligand monoclonal antibody - BiogenCD 40 ligand monoclonal antibody - Biogenhu5c8hu-5c8hu 5c8Humanised CD40 ligand antibody/5c8T cell-B cell activation molecule (T-BAM)